Agreed. But that would depend on how many of cohort 4 that they have adequate data on. Additionally, what does this say about Hep B?
Hoy, isnt the mechanism the same with Hep B, just attacking the MRNA instead of the direct viral RNa as with Hep C? If that's so, does the vector need changed, dose need increased....? What can this mean for Hep B?
Ann: UPDATE ON HCV CLINICAL TRIAL, page-65
-
- There are more pages in this discussion • 46 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)